Access NT-proBNP
BECKMAN COULTER, INC. · Decision date Sep 21, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision for K262109, the Access NT-proBNP assay from Beckman Coulter, Inc., on September 21, 2026, with the submission received June 23, 2026. The device is a Class II B-type natriuretic peptide test system under 21 CFR 862.1117, product code NBC, in the Clinical Chemistry specialty. A 510(k) clearance is not a PMA approval.
The cleared item is a paramagnetic particle, chemiluminescent sandwich immunoassay for quantitative N-terminal pro B-type natriuretic peptide in human serum and plasma on automated Access Immunoassay Analyzers. The comparison table lists the candidate as Access NT-proBNP on the Access 2 Immunoassay System and the predicate as Access NT-proBNP on the DxI 9000 Immunoassay Analyzer (K232164), with the analyzer pairing marked as the difference. The source does not state performance study results or the basis for the SESE determination.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Clinical Chemistry
- Decision date
- Sep 21, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K262109
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- BECKMAN COULTER, INC.
- Product code
- NBC
- Decision code
- SESE
- Decision date
- Sep 21, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Test, Natriuretic Peptide.
- Applicant
- BECKMAN COULTER, INC.
- Product code
- NBC
- FDA device class
- 2
FDA decision timeline
K262109 received
Application receipt date recorded by FDA.
K262109 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code NBC
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Access BNP IIK262597 | BECKMAN COULTER, INC. | 510(k) clearance | Oct 20, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
BECKMAN COULTER, INC.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Chaska, MN
Sources and methodology
- Original FDA record: K262109
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records